



Molecular Detection of *bla*_{OXA-type} Carbapenemase Genes and Antimicrobial Resistance Patterns among Clinical Isolates of *Acinetobacter baumannii*

Maghsoud Kafshnouchi¹ Marzieh Safari² Amir Khodavirdipour³ Abbas Bahador⁴
Seyed Hamid Hashemi⁵ Mohammad Sina Alikhani⁶ Massoud Saidijam⁷ Mohammad Yousef Alikhani²

¹ Department of Microbiology, Maragheh Islamic Azad University, Maragheh, Iran

² Department of Microbiology, Hamadan University of Medical Sciences, Hamadan, Iran

³ Department of Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran

⁴ Department of Microbiology, Tehran University of Medical Sciences, Tehran, Iran

⁵ Department of Infectious Diseases, Hamadan University of Medical Sciences, Hamadan, Iran

⁶ Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran

⁷ Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

Address for correspondence: Mohammad Yousef Alikhani, PhD, Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan 65178-38736, Iran (e-mail: alikhani43@yahoo.com; alikhani@umsha.ac.ir).

Glob Med Genet 2022;9:118–123.

Abstract

Acinetobacter baumannii is a bacterium found in most places, especially in clinics and hospitals, and an important agent of nosocomial infections. The presence of class D enzymes such as OXA-type carbapenemases in *A. baumannii* is proven to have a key function in resistance to carbapenem. The aim of the current study is to determine the *bla*_{OXA-type} carbapenemase genes and antimicrobial resistance among clinically isolated samples of *A. baumannii*. We assessed 100 clinically isolated specimens of *A. baumannii* from patients in intensive care units of educational hospitals of Hamadan, West of Iran. The *A. baumannii* isolates' susceptibility to antibiotics was performed employing disk diffusion method. Multiplex polymerase chain reaction was used to identify the *bla*_{OXA-24-like}, *bla*_{OXA-23-like}, *bla*_{OXA-58-like}, and *bla*_{OXA-51-like} genes. The *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, and *bla*_{OXA-58-like} genes' prevalence were found to be 84, 58, and 3%, respectively. The highest coexistence of the genes was for *bla*_{OXA-51/23} (84%) followed by *bla*_{OXA-51/24-like} (58%). The *bla*_{OXA-51/23-like} pattern of genes is a sort of dominant gene in resistance in *A. baumannii* from Hamadan hospitals. The highest resistance to piperacillin (83%) and ciprofloxacin (81%) has been observed in positive isolates of *bla*_{OXA-23-like}. The *A. baumannii* isolates with *bla*_{OXA-58-like} genes did not show much resistance to antibiotics. Based on the results of the phylogenetic tree analysis, all isolates have shown a high degree of similarity. This study showed the high frequency of OXA-type carbapenemase genes among *A. baumannii* isolates from Hamadan hospitals, Iran. Thus, applying an appropriate strategy to limit the spreading of these strains and also performing new treatment regimens are necessary.

Keywords

- ▶ *Acinetobacter baumannii*
- ▶ nosocomial infection
- ▶ OXA-type carbapenemase

received
September 20, 2021
accepted
October 18, 2021

DOI <https://doi.org/10.1055/s-0041-1740019>
ISSN 2699-9404.

© 2021. The Author(s).

This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (<https://creativecommons.org/licenses/by/4.0/>)
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany

Introduction

Acinetobacter baumannii is an oxidase-negative, gram-negative, nonmotile, nonfermentative coccobacilli and it is found inside most places, especially in hospitals and other health care facilities.¹⁻³ The bacterium is mostly originating from the intensive care units (ICUs). It can cause septicemia, infections of the skin, meningitis, endocarditis, urinary tract infections, soft tissues infections, and ventilator-associated pneumonia in patients in ICU wards.⁴⁻⁷ Therefore, infections caused by the bacterium need early and effective antimicrobial therapy. The carbapenems are the most effective antibacterial agents in the case of clinical isolates of *A. baumannii*.⁸ Nowadays, due to excessive and inappropriate use of these drugs, the resistance to carbapenems has increased.⁹ *A. baumannii* can become carbapenem resistant by the acquisition of plasmid-mediated carbapenem hydrolyzing classes of A, B, and D metallo- β -lactamase enzymes.¹⁰ Class D enzymes such as OXA-type carbapenemases, especially the intrinsic presence of *bla*_{OXA-58-like}, *bla*_{OXA-24-like}, *bla*_{OXA-23-like}, *bla*_{OXA-51}, and β -lactamases in *A. baumannii*, are proven to have a vital role in resistance to carbapenem.¹¹⁻¹³ The OXA-carbapenemase genes can be encoded by chromosome or plasmid and are mostly associated with insertion elements, particularly *ISAbal*.⁸ With the rise of pan-drug-resistant (PDR) and multidrug-resistant (MDR) strains of *A. baumannii* all around the world, the bacterium has become a very serious threat for health care organizations.^{10,14} Thus, the current study focused to discover the *bla*_{OXA-type} carbapenemase genes, which, according to previous studies, contribute to more antibiotic resistance among clinical isolates of *A. baumannii*.

Materials and Methods

Bacterial Isolation and Identification

The cross-sectional research has been performed on 100 *A. baumannii* isolates from clinical specimens in ICU wards in educational hospitals of Hamadan, West of Iran, from December 2016 to December 2017. *A. baumannii* isolates were identified using the biochemical tests and polymerase chain reaction (PCR) targeting the carbapenemase gene of *bla*_{OXA-51-like}.^{15,16}

Susceptibility Testing

The CLSI—Clinical and Laboratory Standards Institute—(CLSI, 2018) method of disk-agar diffusion¹⁷ and interpretation by CLSI breakpoint were used to measure the susceptibility of *A. baumannii* isolates to Meropenem (10 μ g), Imipenem (10 μ g), Amikacin (30 μ g), Gentamicin (10 μ g), Ciprofloxacin (5 μ g), Doxycycline (30 μ g), Piperacillin (100 μ g), Tobramycin (10 μ g), Cefepime (30 μ g), and Ampicillin/sulbactam (20 μ g) antimicrobial agents. ATCC 27853-*Pseudomonas aeruginosa* was deployed in susceptibility testing as the control strain.

Multiplex-PCR Assay

Alkaline lysis method was used for extraction of deoxyribonucleic acid (DNA).¹⁵ The primers for PCR amplification of *bla*_{OXA-58-like}, *bla*_{OXA-23-like}, *bla*_{OXA-51-like}, and *bla*_{OXA-24-like} were used as described before (►Table 1).¹⁸

Multiplex-PCR was performed in a 50- μ L reaction volume containing 5 μ L PCR buffer 10X with MgCl₂, 5 μ L deoxynucleotide triphosphates (2 mM), 2 μ L from each reverse and forward primers (10 pmol), 0.4 μ L Taq Polymerase (5U/ μ L), 6 μ L DNA template, and 29.6 μ L nuclease-free deionized water. The amplification conditions were as follows: initial denaturation at 94°C for 5 minutes followed by 30 cycles at 94°C for 30 seconds, 53°C for 40 seconds, and 72°C for 50 seconds and a final extension at 72°C for 6 minutes. Gel electrophoresis of the amplicons was performed on 1.5% agarose gel. The findings were analyzed employing a transilluminator device. Bands with 353 bp, 501 bp, 246 bp, and 599 bp were the representatives of *bla*_{OXA-51-like}, *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, and *bla*_{OXA-58-like}, respectively.

Sequencing

Three PCR products of each gene, which was separately performed, were purified and sequenced directly by Sanger dideoxy-sequencing technology in two directions using a capillary DNA analyzer (Applied Biosystems, Waltham, Massachusetts, United States).

Phylogenetic Analysis of OXA-type Variant

The phylogenetic analysis was conducted independently for the OXA-type variant. The tree is drawn to scale, with branch lengths measuring the number of substitutions per site. The sequences were aligned and manually edited in consensus positions and compared with that of the sequences from

Table 1 Primer sequences used for multiplex polymerase chain reaction amplification of *bla*_{OXA} genes variants

Primer name		5' to 3' sequence prime	Product size (bp)	Annealing temperature (°C)	Reference
OXA-51-like	F	TAATGCTTTGATCGGCCTTG	353	53	Woodford (2006) ¹⁸
	R	TGGATTGCACTTCATCTTGG			
OXA-23-like	F	GATCGGATTGGAGAACCAGA	501	53	Woodford (2006) ¹⁸
	R	ATTTCTGACCGCATTTCAT			
OXA-24-like	F	GGTTAGTTGGCCCCCTTAAA	246	53	Woodford (2006) ¹⁸
	R	AGTTGAGCGAAAAGGGGATT			
OXA-58-like	F	AAGTATTGGGGCTGTGCTG	599	53	Woodford (2006) ¹⁸
	R	CCCCTCTGCGCTCTACATAC			

GenBank. A phylogenetic tree was built by the maximum likelihood method utilizing the Tamura-Nei model with Mega software (v.7).¹⁹

Statistical Analysis

Statistical analysis was done using Statistical Package for the Social Sciences 23.0 (SPSS, Chicago, Illinois, United States). The Pearson chi-squared test and Fisher's exact test were used to analyze the qualitative data. All *p*-values < 0.05 were considered statistically significant.

Results

The highest resistance to piperacillin (83%) and ciprofloxacin (81%) has been observed in *bla*OXA23-like, and the highest resistance and sensitivity were observed for ciprofloxacin (57%) and ampicillin/sulbactam (28%) in *bla*OXA-24-like positive *A. baumannii* isolates, respectively. The *A. baumannii* isolates with *bla*OXA-58-like genes did not show much resistance to antibiotics. Considering the presence of the studied genes, 3, 58, and 84% of the 100 samples were carrying *bla*OXA-58-like, *bla*OXA-24-like, and *bla*OXA-23-like genes, respectively (► Fig. 1 and ► Table 2). Among the 100 *A. baumannii* isolates, 97.9% of the imipenem-resistant isolates were positive for at least one OXA-type gene. Moreover, 95.9% and 1% of the meropenem and colistin sulfate resistant isolates were carrying OXA-type genes.

Results of Phylogenetic Tree Analysis of OXA-type Variant

The sequences received from the isolates were confirmed as the OXA-type variants and were deposited in the GenBank under the accession numbers as follows: *bla*_{OXA-51-like}: KJ451411, KJ451412, and KJ451413; *bla*_{OXA-23-like}: KJ451414 and KJ451415; and *bla*_{OXA-24-like}: KJ451416, KJ451417, and KJ451418 (► Fig. 2). Analysis of the phylogenetic tree demonstrates that all isolates have shown a high degree of similarity.

Correlation between Contributions of *bla*_{OXA} Genes with Antibiotic Resistance

The relationship between *bla*OXA-types and resistance to different antibiotics was determined by statistical analysis.




Fig. 1 Gel electrophoresis of the *bla*OXA gene among the *Acinetobacter baumannii* isolates. M: 50 bp marker; 1–10: the isolates; 11: negative control. Bands with 501 bp, 246 bp, and 599 bp are the representatives of *bla*OXA-23-like, *bla*OXA-24-like, and *bla*OXA-58-like, respectively.

Table 2 OXA-type patterns among carbapenem-resistant *Acinetobacter baumannii* isolates

Gene pattern	No (%)
OXA-51	100 (100)
OXA-23	84 (84)
OXA-58	3 (3)
OXA-24	58 (58)
OXA-51/OXA-23	84 (84)
OXA-51/OXA-24	58 (58)
OXA-51/OXA-58	3 (3)
OXA-51/OXA-23/OXA-24	5 (5)
OXA-51/OXA-24/OXA-58	2 (2)
OXA-51/OXA-23/OXA-24/OXA-58	1 (1)




Fig. 2 Phylogenetic tree built based on the sequence isolates by maximum likelihood method using the Tamura-Nei model. Based on the results, all isolates have shown a high degree (95–100%) of similarity.

The prevalence of oxacillinases enzymes encoding genes in antibiotic-resistant isolates was higher than the susceptible strains, but there was no statistically significant relationship (► Table 3).

Discussion

Currently, carbapenem resistance in *A. baumannii* isolates has become a worldwide problem. This study's results demonstrated that significant numbers of clinical isolates of *A. baumannii*, especially resistant to imipenem and meropenem isolates, were affirmative for the variety of OXA gene expressions. Commonly, the carbapenem antibiotics are highly active against *A. baumannii* isolates and resistant to β -lactamase enzymes. However, the resistance to these compounds is a problematic issue and is not a result of the presence of a distinct mechanism, while a combination of diverse mechanisms such as enzymatic and nonenzymatic ones are involved. The most significant mechanism of resistance to carbapenems is the enzymatic hydrolysis, arbitrated by the carbapenemases.^{11,20} Recently, the number of β -lactamase enzymes in class D has increased significantly. Some of the OXA-type carbapenemases are widely found in *A. baumannii* isolates. However, many of the OXA-type

Table 3 Statistical analysis of the correlation between the presence of blaOXA-type genes and antibiotic resistance in *Acinetobacter baumannii* isolates

Gene	OXA23		Fisher exact test	Exact sig.(two-sided)	OXA24		Fisher exact test	Exact sig.(two-sided)	OXA58		Fisher exact test	Exact sig.(two-sided)
	Positive	Negative			Positive	Negative			Positive	Negative		
Meropenem	R	79%	0.671	0.692	56%	37%	1.855	0.374	3%	90%	1.608	1
	I	2%			2%	0%			0%	2%		
	S	4%			2%	3%			0%	5%		
Imipenem	R	73%	2.37	0.429	52%	33%	2.066	0.351	2%	83%	2.799	0.389
	I	1%			2%	0%			0%	2%		
	S	11%			6%	7%			1%	12%		
Amikacin	R	72%	1.422	0.443	51%	33%	1.099	0.703	2%	82%	3.212	0.217
	I	8%			6%	3%			0%	9%		
	S	5%			3%	4%			1%	6%		
Gentamicin	R	74%	2.33	0.324	54%	23%	3.58	0.116	3%	84%	1.29	1
	I	1%			2%	0%			0%	2%		
	S	10%			4%	7%			1%	11%		
Ciprofloxacin	R	81%	1.37	0.549	57%	38%	1.75	0.580	3%	92%	2.374	1
	I	1%			0%	1%			0%	1%		
	S	4%			3%	1%			0%	4%		
Doxycycline	R	24%	2.45	0.320	18%	11%	0.287	0.902	1%	28%	2.092	0.387
	I	34%			21%	16%			0%	37%		
	S	27%			21%	13%			2%	32%		
Piperacillin	R	83%	1.117	1	59%	39%	2.033	0.642	3%	95%	3.541	1
	I	1%			1%	0%			0%	1%		
	S	1%			0%	1%			0%	1%		
Tobramycin	R	65%	1.386	0.575	47%	29%	0.824	0.676	3%	73%	1.19	1
	I	2%			2%	1%			0%	3%		
	S	18%			11%	10%			0%	21%		
Cefepime	R	79%	2.089	0.443	55%	37%	0.501	1	3%	89%	1.50	1
	I	4%			4%	2%			0%	6%		
	S	2%			1%	1%			0%	2%		
Amp/sul	R	30%	2.94	0.243	21%	12%	1.20	0.561	0%	33%	3.098	0.155
	I	20%			11%	11%			2%	20%		
	S	25%			28%	17%			1%	44%		

Abbreviations: Amp/sul, ampicillin/sulbactam; I, intermediate; R, resistant; S, sensitive; sig., significance.

carbapenemases illustrate simply weak catalytic activity, but resistance to carbapenems may be caused by a combined action of different OXA-type carbapenemase.²¹ Feizabadi et al in 2008 studied the susceptibility to antimicrobial and *bla*OXA genes distribution among *Acinetobacter* spp. in Tehran hospitals. They reported the coexistence of *bla*_{OXA-51/23} and *bla*_{OXA-51/24-like} in 25% ($n = 32$) and 17.9% ($n = 23$) of their studied isolates, respectively. Over 70% of their studied carbapenem-resistant isolates had at least two genes encoding OXA-type carbapenemase.²² In our study, the highest coexistence was for *bla*_{OXA-51/23} (84%) followed by *bla*_{OXA-51/24-like} (58%), which is considerably higher than their report from Tehran and indicates an elevation in the prevalence of *A. baumannii* isolates carrying these genes over the time. In the current research, comparable to another research performed in Iran, the most commonly found OXA-type carbapenemase was OXA-23 among other carbapenem-resistant isolates, next to OXA-24.^{23,24} Zafari et al reported a high prevalence of OXA-type carbapenemases among *A. baumannii* isolates in Tehran in 2017. They studied *bla*_{OXA-51-like}, *bla*_{OXA-58-like}, *bla*_{OXA-23-like}, and *bla*_{OXA-24-like} genes among 100 isolates of carbapenem-resistant *A. baumannii*. All of their studied carbapenem-resistant *A. baumannii* isolates were MDR and extensively drug-resistant and even 2% of the isolates were PDR. The *bla*_{OXA-24-like} and *bla*_{OXA-23-like} prevalence genes were reported to be 22% and 81%, respectively. They concluded that there are very few therapeutic options for the treatment of carbapenem-resistant *A. baumannii* infections.²³ In the present study, just similar to the findings of Zafari et al in Tehran, 84, 58, and 3% of the *A. baumannii* isolates from Hamadan, west of Iran, were carrying *bla*_{OXA-23-like}, *bla*_{OXA-24-like}, and *bla*_{OXA-58-like} genes, respectively. The very high prevalence of drug resistance among *A. baumannii* isolates was reported in Hamadan in 2013.²⁴ Bardbari et al investigated the OXA-type gene presence including *bla*_{OXA-58} and *bla*_{OXA-23}, *bla*_{OXA-24} among 75 clinical and 32 environmental strains of the *A. baumannii* isolates in Hamadan in 2017. Their results showed that 80.4, 30.8, 0, and 30.8% of their studied *A. baumannii* isolates have *bla*_{OXA-23/24}, *bla*_{OXA-24}, *bla*_{OXA-23}, and *bla*_{OXA-58} genes.²⁵ Their results are similar to the finding of the present study. Given the fact that both studies are conducted in the same area but on different isolates, the similar results can be explained. In a study that was prepared by Zowawi et al, OXA-23 was identified as the highest type (91.5%) of carbapenemases in carbapenem-resistant *A. baumannii* isolates from hospitals of Bahrain, Saudi Arabia, Oman, Kuwait, United Arab Emirates, and Qatar followed by OXA-24 (4.3%).²⁶ Also, research works from other countries have reported that OXA-23 as a dominant type in carbapenem-resistant isolates has been accompanying outbreaks.^{27,28} Similar to our results, some studies have reported the low prevalence of OXA-58 among carbapenem-resistant isolates from the east (0.5%), and north-west of Iran (3.2%).^{26,29} The outcome of our research confirmed the high prevalence of OXA-type carbapenemase between carbapenem antibiotic-resistant *A. baumannii* bacteria; furthermore, correct prescription of antibiotics and effective infection control monitors for preventing the extent of resistant isolates are required.

Conclusion

This study's results demonstrated that carbapenem resistance is increasing among *A. baumannii* clinical isolates in our area and is often associated with multidrug resistance. Moreover, the diversity of *bla*OXA genes was high among these isolates and OXA-23 is the most important carbapenemase mechanism responsible for the resistance phenotype.

Consent for Publication

All authors consented for publication of the above paper.

Availability of Data and Material

All data generated or analyzed during this study are included in this published article.

Authors' Contributions

M.Y.A. designed the study, edited the manuscript. M.S. and A.B. were scientific advisor on molecular genetics section. M.K., M.S., and M.S.A. collaborated in collecting samples and doing experiments. S.H.H. collaborated on patient introduction and clinical examination. A.K. wrote the scientific draft and checked the English use and grammar of the manuscript.

Funding

The present study was supported financially by the Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, Hamadan, Iran.

Conflict of Interest

None declared.

Acknowledgment

The authors would like to acknowledge the Vice-Chancellor of Research and Technology, Hamadan University of Medical Sciences, Hamadan, Iran, for the financial support to the present study.

References

- Perez F, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2007;51(10):3471–3484
- Yeom J, Shin JH, Yang JY, Kim J, Hwang GS. (1)H NMR-based metabolite profiling of planktonic and biofilm cells in *Acinetobacter baumannii* 1656-2. *PLoS One* 2013;8(03):e57730
- Poiré L, Bonnin RA, Nordmann P. Genetic basis of antibiotic resistance in pathogenic *Acinetobacter* species. *IUBMB Life* 2011;63(12):1061–1067
- Gulati S, Kapil A, Das B, Dwivedi SN, Mahapatra AK. Nosocomial infections due to *Acinetobacter baumannii* in a neurosurgery ICU. *Neurol India* 2001;49(02):134–137
- Rodríguez Guardado A, Maradona JA, Asensi V, et al. [Postsurgical meningitis caused by *Acinetobacter baumannii*: study of 22 cases and review of the literature]. *Rev Clin Esp* 2001;201(09):497–500
- Wang KW, Chang WN, Huang CR, et al. Post-neurosurgical nosocomial bacterial meningitis in adults: microbiology, clinical features, and outcomes. *J Clin Neurosci* 2005;12(06):647–650
- Krol V, Hamid NS, Cunha BA. Neurosurgically related nosocomial *Acinetobacter baumannii* meningitis: report of two cases and literature review. *J Hosp Infect* 2009;71(02):176–180

- 8 Poirel L, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. *Antimicrob Agents Chemother* 2010;54(01):24–38
- 9 Shahcheraghi F, Aslani MM, Mahmoudi H, et al. Molecular study of carbapenemase genes in clinical isolates of Enterobacteriaceae resistant to carbapenems and determining their clonal relationship using pulsed-field gel electrophoresis. *J Med Microbiol* 2017; 66(05):570–576
- 10 Bertini A, Poirel L, Mugnier PD, Villa L, Nordmann P, Carattoli A. Characterization and PCR-based replicon typing of resistance plasmids in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2010;54(10):4168–4177
- 11 Opazo A, Domínguez M, Bello H, Amyes SG, González-Rocha G. OXA-type carbapenemases in *Acinetobacter baumannii* in South America. *J Infect Dev Ctries* 2012;6(04):311–316
- 12 Brown S, Young HK, Amyes SG. Characterisation of OXA-51, a novel class D carbapenemase found in genetically unrelated clinical strains of *Acinetobacter baumannii* from Argentina. *Clin Microbiol Infect* 2005;11(01):15–23
- 13 Higgins PG, Poirel L, Lehmann M, Nordmann P, Seifert H. OXA-143, a novel carbapenem-hydrolyzing class D beta-lactamase in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 2009;53(12):5035–5038
- 14 Howard A, O'Donoghue M, Feeney A, Sleator RD. *Acinetobacter baumannii*: an emerging opportunistic pathogen. *Virulence* 2012;3(03):243–250
- 15 Safari M, Mozaffari Nejad AS, Bahador A, Jafari R, Alikhani MY. Prevalence of ESBL and MBL encoding genes in *Acinetobacter baumannii* strains isolated from patients of intensive care units (ICU). *Saudi J Biol Sci* 2015;22(04):424–429
- 16 Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL. Identification of *Acinetobacter baumannii* by detection of the blaOXA-51-like carbapenemase gene intrinsic to this species. *J Clin Microbiol* 2006;44(08):2974–2976
- 17 CLSI. Performance Standards for Antimicrobial Susceptibility Testing, 28th edition. CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2018
- 18 Woodford N, Ellington MJ, Coelho JM, et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents* 2006;27(04):351–353
- 19 Tamura K, Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. *Mol Biol Evol* 1993;10(03):512–526
- 20 Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev* 2007;20(03):440–458table of contents.
- 21 Walther-Rasmussen J, Høiby N. OXA-type carbapenemases. *J Antimicrob Chemother* 2006;57(03):373–383
- 22 Feizabadi MM, Fathollahzadeh B, Taherikalani M, et al. Antimicrobial susceptibility patterns and distribution of blaOXA genes among *Acinetobacter* spp. isolated from patients at Tehran hospitals. *Jpn J Infect Dis* 2008;61(04):274–278
- 23 Zafari M, Feizabadi MM, Jafari S, Abdollahi A, Sabokbar A. High prevalence of OXA-type carbapenemases among *Acinetobacter baumannii* strains in a teaching hospital of Tehran. *Acta Microbiol Immunol Hung* 2017;64(04):385–394
- 24 Safari M, Saidijam M, Bahador A, Jafari R, Alikhani MY. High prevalence of multidrug resistance and metallo-beta-lactamase (MBL) producing *Acinetobacter baumannii* isolated from patients in ICU wards, Hamadan, Iran. *J Res Health Sci* 2013;13(02): 162–167
- 25 Bardbari AM, Arabestani MR, Karami M, et al. Highly synergistic activity of melittin with imipenem and colistin in biofilm inhibition against multidrug-resistant strong biofilm producer strains of *Acinetobacter baumannii*. *Eur J Clin Microbiol Infect Dis* 2018; 37(03):443–454
- 26 Zowawi HM, Sartor AL, Sidjabat HE, Balkhy HH, Walsh TR, Al Johani SM, et al. Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolates in the Gulf Cooperation Council States: dominance of OXA-23-type producers. *J Clin Microbiol* 2015;53:896–903
- 27 Merino M, Poza M, Roca I, et al. Nosocomial outbreak of a multi-resistant *Acinetobacter baumannii* expressing OXA-23 carbapenemase in Spain. *Microb Drug Resist* 2014;20(04):259–263
- 28 Dettori M, Piana A, Deriu MG, et al. Outbreak of multidrug-resistant *Acinetobacter baumannii* in an intensive care unit. *New Microbiol* 2014;37(02):185–191
- 29 Kooti S, Motamedifar M, Sarvari J. Antibiotic resistance profile and distribution of oxacillinase genes among clinical isolates of *Acinetobacter baumannii* in Shiraz teaching hospitals, 2012–2013. *Jundishapur J Microbiol* 2015;8(08):e20215